Viral Hepatitis

You have full text access to this OnlineOpen article

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development†

  1. Leen Delang1,
  2. Jan Paeshuyse1,
  3. Inge Vliegen1,
  4. Pieter Leyssen1,
  5. Susan Obeid1,
  6. David Durantel2,
  7. Fabien Zoulim2,
  8. Anne Op de Beeck3,
  9. Johan Neyts1,‡,*

Article first published online: 18 FEB 2009

DOI: 10.1002/hep.22916

Issue

Hepatology

Hepatology

Volume 50, Issue 1, pages 6–16, July 2009

Additional Information

How to Cite

Delang, L., Paeshuyse, J., Vliegen, I., Leyssen, P., Obeid, S., Durantel, D., Zoulim, F., Op de Beeck, A. and Neyts, J. (2009), Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology, 50: 6–16. doi: 10.1002/hep.22916

Author Information

  1. 1

    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

  2. 2

    INSERM, U871, Lyon, France; Université Lyon 1, IFR62 Lyon-Est, Lyon, France; Hospices Civils de Lyon, Hôtel Dieu, Service d'hépatologie et de gastroentérologie, Lyon, France

  3. 3

    Virology Unit, Laboratory of Epigenetic of Cancer, Faculty of Medicine, ULB, Belgium

  1. ‡

    fax: 32-16-337340

*Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 23 JUN 2009
  2. Article first published online: 18 FEB 2009
  3. Accepted manuscript online: 18 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 11 FEB 2009
  5. Manuscript Received: 12 SEP 2008

Funded by

  • Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen and FWO
  • VIRGIL
  • European Network of Excellence on Antiviral Drug Resistance (Priority 1 Life Sciences, Genomics and Biotechnology). Grant Number: LSHM-CT-2004-503359
  • Fonds National de la Recherche Scientifique. Grant Number: No.3.4.545.06.F

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1645K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James H. Lewis, Clinical Perspective: Statins and the Liver—Harmful or Helpful?, Digestive Diseases and Sciences, 2012,

    CrossRef

  2. 2
    Leen Delang, Mathy Froeyen, Piet Herdewijn, Johan Neyts, Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase, Antiviral Research, 2012, 93, 1, 30

    CrossRef

  3. 3
    Leen Delang, Inge Vliegen, Pieter Leyssen, Johan Neyts, In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors, Journal of Hepatology, 2012, 56, 1, 41

    CrossRef

  4. 4
    Matthieu Blanchet, Nabil G. Seidah, Patrick Labonté, SKI-1/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus replication, Antiviral Research, 2012,

    CrossRef

  5. 5
    Darius Moradpour, François Penin, Charles Rice, Zakim and Boyer's Hepatology, 2012,

    CrossRef

  6. 6
    Hans L. Tillmann, John G. McHutchison, Zakim and Boyer's Hepatology, 2012,

    CrossRef

  7. 7
    Akira Honda, Yasushi Matsuzaki, Cholesterol and chronic hepatitis C virus infection, Hepatology Research, 2011, 41, 8
    Direct Link:
  8. 8
    Ya-Jean Wang, Kao-Lu Pan, Tsung-Chih Hsieh, Teng-Yuan Chang, Wen-Hsing Lin, John T.-A. Hsu, Diosgenin, a Plant-Derived Sapogenin, Exhibits Antiviral Activityin Vitroagainst Hepatitis C Virus, Journal of Natural Products, 2011, 74, 4, 580

    CrossRef

  9. 9
    Margaret F. Bassendine, David A. Sheridan, Daniel J. Felmlee, Simon H. Bridge, Geoffrey L Toms, R. Dermot G. Neely, HCV and the hepatic lipid pathway as a potential treatment target, Journal of Hepatology, 2011, 55, 6, 1428

    CrossRef

  10. 10
    José A. Campo, Mohamed Eslam, Manuel Romero-Gómez, Hepatitis C Virus and Statins: Is There a Role?, Current Hepatitis Reports, 2011, 10, 3, 162

    CrossRef

  11. 11
    S. Obeid, S. S. Printsevskaya, E. N. Olsufyeva, K. Dallmeier, D. Durantel, F. Zoulim, M. N. Preobrazhenskaya, J. Neyts, J. Paeshuyse, Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics, Journal of Antimicrobial Chemotherapy, 2011, 66, 6, 1287

    CrossRef

  12. 12
    Jonathan Goldwasser, Pazit Y. Cohen, Wenyu Lin, Danny Kitsberg, Patrick Balaguer, Stephen J. Polyak, Raymond T. Chung, Martin L. Yarmush, Yaakov Nahmias, Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism, Journal of Hepatology, 2011, 55, 5, 963

    CrossRef

  13. 13
    K. Patel, R. Jhaveri, J. George, G. Qiang, C. Kenedi, K. Brown, C. Cates, A. Zekry, H. L. Tillmann, L. Elliott, R. Kilaru, J. Albrecht, A. Conrad, J. G McHutchison, Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C, Journal of Viral Hepatitis, 2011, 18, 5
    Direct Link:
  14. 14
    Gowtham A. Rao, Prashant K. Pandya, Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C, Gastroenterology, 2011, 140, 1, 144

    CrossRef

  15. 15
    Mohammed Eslam, Luis F. López-Cortés, Manuel Romero-Gomez, The role of insulin resistance in HIV/hepatitis C virus-coinfected patients, Current Opinion in HIV and AIDS, 2011, 6, 6, 553

    CrossRef

  16. 16
    Shu-Chang An, Li-Li Xu, Feng-Di Li, Lin-Lin Bao, Chuan Qin, Zhan-Cheng Gao, Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic, Medical Hypotheses, 2011, 77, 6, 1054

    CrossRef

  17. 17
    Ann S. Desplanques, Maria Pontes, Natasha De Corte, Nele Verheyen, Hans J. Nauwynck, Dries Vercauteren, Herman W. Favoreel, Cholesterol depletion affects infectivity and stability of pseudorabies virus, Virus Research, 2010, 152, 1-2, 180

    CrossRef

  18. 18
    Tatsuya Fujino, Makoto Nakamuta, Ryoko Yada, Yoko Aoyagi, Kenichiro Yasutake, Motoyuki Kohjima, Kunitaka Fukuizumi, Tsuyoshi Yoshimoto, Naohiko Harada, Masayoshi Yada, Masaki Kato, Kazuhiro Kotoh, Akinobu Taketomi, Yoshihiko Maehara, Manabu Nakashima, Munechika Enjoji, Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver, Hepatology Research, 2010, 40, 9
    Direct Link:
  19. 19
    Hisashi Moriguchi, Raymond T Chung, Chifumi Sato, New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells, Hepatology, 2010, 51, 1
    Direct Link:
  20. 20
    Stephen A. Harrison, Lorenzo Rossaro, Ke-Qin Hu, Keyur Patel, Hans Tillmann, Sandeep Dhaliwal, Dawn M. Torres, Kenneth Koury, Venkata S. Goteti, Stephanie Noviello, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Mark S. Sulkowski, Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy, Hepatology, 2010, 52, 3
    Direct Link:
  21. 21
    Ted Bader, Brent Korba, Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro, Antiviral Research, 2010, 86, 3, 241

    CrossRef

  22. 22
    Enzo Emanuele, Statins and hepatitis C virus: Friend or foe?, Hepatology, 2010, 51, 1
    Direct Link:
  23. 23
    Stephen D. Woodhouse, Ramamurthy Narayan, Sally Latham, Sheena Lee, Robin Antrobus, Bevin Gangadharan, Shujun Luo, Gary P. Schroth, Paul Klenerman, Nicole Zitzmann, Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro, Hepatology, 2010, 52, 2
    Direct Link:
View Full Article (HTML) Get PDF (1645K)